Drugs / S103 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07587125 | May 2026 → Nov 2027 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Xijing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S103 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587125 ↗ |
| Known as | S103 CAR-T | “then receive S103 CAR-T cell infusion.” NCT07587125 ↗ |
| Modality | Cell therapy | “S103（BCMA-CAR T ）cells” NCT07587125 ↗ |